Earlier this month, Lantheus agreed to acquire Life Molecular Imaging for an upfront payment of $350m, which is expected to ...

Through the transaction, Lantheus has acquired OCTEVY, a registrational-stage PET diagnostic imaging agent targeting neuroendocrine tumors, which complements Lantheus’ therapeutic candidate ...

Riley lowered the firm’s price target on Lantheus (LNTH ... Gozellix received FDA approval for the next-generation PSMA-PET imaging agent for prostate cancer, and the firm will closely watch ...

"We are excited to be partnering with Lantheus to bring Granzyme B PET imaging to the forefront. This strategic collaboration creates a clear path to commercialization with an ideal partner in the ...

Lantheus' pipeline-building drive in radiopharma ... which was extended last year with the acquisition of NTI-1309, a PET oncology imaging agent that targets cancer biomarker fibroblast activation ...

Evergreen is a clinical-stage radiop Enhances Lantheus’ growth profile with Neuraceq®, a globally approved F-18 PET imaging agent used to detect beta-amyloid plaques in patients evaluated for ...

MK-6420. Lantheus is also attempting to expand its radiopharmaceutical diagnostic offerings, the most notable of which is MK-6420, a second-generation F18-labeled PET imaging agent that targets ...